Cellectar Biosciences Inc (CLRB)
Cellectar Biosciences Inc (CLRB) is a NASDAQ-listed biotechnology company in the healthcare sector. The company security is common stock, meaning it is a common equity instrument tied to ownership in the business rather than a fund, note, or other security type. Cellectar Biosciences focuses on developing cancer-related therapies and research programs within clinical biopharmaceutical work. Its business is centered on oncology-focused drug development and related scientific efforts, with an emphasis on targeted approaches to treatment. Investors should view CLRB as an operating company security linked to a biotechnology issuer and its research pipeline, not as a fixed-income or pooled investment product.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CLRB
|
$1.94
|
-25.9% Downside
|
Overvalued
|
$11.50
|
339.8% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 19, 2026
|
-1.0x
|
7.5x
|
—
|
20.139 M
|
16.103 M
|
6.5%
|
97.8%
|
-38.9
|
—
|
89.2%
|
